{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8395","upperLimit":"0.9572","value":"0.8984"},{"groupId":"OG001","lowerLimit":"0.5348","upperLimit":"0.9946","value":"0.7647"},{"groupId":"OG002","lowerLimit":"0.4818","upperLimit":"0.7341","value":"0.6079"},{"groupId":"OG003","lowerLimit":"0.3951","upperLimit":"0.5796","value":"0.4873"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"110"},{"groupId":"OG003","value":"196"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy or death after 5 years since enrollment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery","id":"OG000","title":"Arm A: No Adjuvant Treatment"},{"description":"Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy","id":"OG001","title":"Arm B: Low Risk; Adjuvant Radiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"OG002","title":"Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"OG003","title":"Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy"}],"paramType":"NUMBER","populationDescription":"Ineligible patients are excluded as well as patients who were treated on the incorrect arm.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Probability for Event Free Survival.","type":"PRIMARY","unitOfMeasure":"Probability of EFS at 5 years"}